Cancer risks among BRCA1 and BRCA2 mutation carriers.

Mammographic density, breast cancer risk and risk prediction. Breast Cancer Res (2007) 2.71

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol (2013) 1.55

The role of DNA damage repair in aging of adult stem cells. Nucleic Acids Res (2007) 1.35

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res (2014) 1.18

Triple-negative breast cancer: new perspectives for targeted therapies. Onco Targets Ther (2015) 1.14

An update on PARP inhibitors for the treatment of cancer. Onco Targets Ther (2015) 1.14

Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner. Clin Cancer Res (2009) 1.08

Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: the Saudi Arabia experience. BMC Cancer (2007) 1.08

Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nat Genet (2015) 1.05

Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase beta is accentuated by BRCA2 mutation. Cancer Res (2009) 1.02

Characterization of BRCA1 protein targeting, dynamics, and function at the centrosome: a role for the nuclear export signal, CRM1, and Aurora A kinase. J Biol Chem (2012) 0.97

BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. J Clin Invest (2016) 0.94

Mitochondrial DNA variant interactions modify breast cancer risk. J Hum Genet (2008) 0.90

Implication of BRCA2 -26G>A 5' untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphism. Breast Cancer Res (2007) 0.89

A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer. BMC Cancer (2010) 0.89

Genetic tests: clinical validity and clinical utility. Curr Protoc Hum Genet (2014) 0.88

Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study. Fam Cancer (2010) 0.88

Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort. Mod Pathol (2016) 0.87

BRCA1 and BRCA2 families and the risk of skin cancer. Fam Cancer (2010) 0.86

MUTYH gene variants and breast cancer in a Dutch case–control study. Breast Cancer Res Treat (2012) 0.85

Men in the women's world of hereditary breast and ovarian cancer--a systematic review. Fam Cancer (2009) 0.84

Novel sequence variants and a high frequency of recurrent polymorphisms in BRCA1 gene in Sri Lankan breast cancer patients and at risk individuals. BMC Cancer (2008) 0.84

Diagnosis of Fanconi Anemia: Mutation Analysis by Multiplex Ligation-Dependent Probe Amplification and PCR-Based Sanger Sequencing. Anemia (2012) 0.84

Hereditary breast cancer in the Han Chinese population. J Epidemiol (2013) 0.83

BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing. Oncologist (2015) 0.82

Novel sequence variants and common recurrent polymorphisms of BRCA2 in Sri Lankan breast cancer patients and a family with BRCA1 mutations. Exp Ther Med (2011) 0.81

Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2014) 0.80

An Autoimmune Response Signature Associated with the Development of Triple-Negative Breast Cancer Reflects Disease Pathogenesis. Cancer Res (2015) 0.80

Whole exome sequencing reveals concomitant mutations of multiple FA genes in individual Fanconi anemia patients. BMC Med Genomics (2014) 0.79

The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat (2012) 0.78

Age of 40 years or younger is an independent risk factor for locoregional failure in early breast cancer: a single-institutional analysis in saudi arabia. J Oncol (2012) 0.78

Molecular insights into the aetiology of female reproductive ageing. Nat Rev Endocrinol (2015) 0.78

40 years of progress in female cancer death risk: a Bayesian spatio-temporal mapping analysis in Switzerland. BMC Cancer (2015) 0.78

The frequency of BRCA1 founder mutation c.5266dupC (5382insC) in breast cancer patients from Ukraine. Hered Cancer Clin Pract (2015) 0.77

Religiosity, spirituality, and psychological distress in African-Americans at risk for having a hereditary cancer predisposing gene mutation. Am J Med Genet C Semin Med Genet (2009) 0.77

Treatment of breast cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: a case report. BMC Res Notes (2016) 0.75

Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer. F1000Res (2017) 0.75

Ataxia telangiectasia mutated (ATM), could it be another useful biomarker for the successful treatment with the poly (ADP-ribose) polymerase inhibitor? Transl Gastroenterol Hepatol (2016) 0.75

Constitutive expression of AhR and BRCA-1 promoter CpG hypermethylation as biomarkers of ERα-negative breast tumorigenesis. BMC Cancer (2015) 0.75

Cancer worry among Norwegian male BRCA1/2 mutation carriers. Fam Cancer (2011) 0.75

gDNA enrichment by a transposase-based technology for NGS analysis of the whole sequence of BRCA1, BRCA2, and 9 genes involved in DNA damage repair. J Vis Exp (2014) 0.75

Genetic evaluation of BRCA1 associated a complex genes with triple-negative breast cancer susceptibility in Chinese women. Oncotarget (2016) 0.75

Effects of Radiation Therapy on Breast Epithelial Cells in BRCA1/2 Mutation Carriers. Breast Cancer (Auckl) (2015) 0.75

Rapid and cost effective screening of breast and ovarian cancer genes using novel sequence capture method in clinical samples. Fam Cancer (2014) 0.75

Prevalence of two BRCA1 mutations, 5382insC and 300T > G, in ovarian cancer patients from Ukraine. Fam Cancer (2017) 0.75

Mutations, evolution and the central role of a self-defined fitness function in the initiation and progression of cancer. Biochim Biophys Acta (2017) 0.75

Is Low FMR1 CGG Repeat Length in Males Correlated with Family History of BRCA-Associated Cancers? An Exploratory Analysis of Medical Records. J Genet Couns (2017) 0.75

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med (1997) 13.96

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science (2003) 13.19

Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 9.06

Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst (1999) 8.15

On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst (2002) 7.64

Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst (2002) 6.58

Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet (2001) 3.75

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2002) 3.25

Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. J Clin Oncol (2006) 2.81

Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet (2005) 2.65

Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol (2004) 2.25

Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst (2006) 2.25

Understanding breast cancer risk -- where do we stand in 2005? J Cell Mol Med (2005) 2.21

Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. Proc Natl Acad Sci U S A (2006) 1.99

Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol (2006) 1.79

BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst (2004) 1.76

Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer (2002) 1.63

Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer (2005) 1.48

Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2004) 1.34

Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma. Invest Ophthalmol Vis Sci (2003) 1.28

Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control (2005) 1.20

Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev (2005) 1.16

Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer (2004) 1.10

Cancer risks in BRCA1 carriers: time for the next generation of studies. J Natl Cancer Inst (2002) 1.06

Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians. Breast Cancer Res Treat (2006) 1.05

The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res (2004) 1.04

The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2006) 0.96

Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing. Eur J Cancer (2005) 0.89

Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med (1991) 7.17

Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig complement. Science (1968) 3.69

Somatic mutations in the neurofibromatosis 1 gene in human tumors. Cell (1992) 3.20

Multi-disciplinary clinical study of Smith-Magenis syndrome (deletion 17p11.2) Am J Med Genet (1996) 3.17

A hemodynamic model of the pathogenesis of age-related macular degeneration. Am J Ophthalmol (1997) 3.11

Can the uptake of breast screening by Asian women be increased? A randomized controlled trial of a linkworker intervention. J Public Health Med (1994) 3.04

Managed care: devils, angels, and the truth in between. Health Prog (1999) 2.68

Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study. BMJ (1998) 2.61

Experience with nontreatment of central serous choroidopathy. Arch Ophthalmol (1974) 2.51

Pigmentary epitheliopathy and erythema nodosum. Arch Ophthalmol (1971) 2.39

Detection and surveillance of colorectal cancer. JAMA (1989) 2.07

Adenovirus-mediated gene transfer to ciliated airway epithelia requires prolonged incubation time. J Virol (1996) 1.98

Case report. Metastatic pulmonary calcification in renal failure: a new HRCT pattern. Br J Radiol (2002) 1.95

The International Collaborative Study of Maternal Phenylketonuria: status report 1998. Eur J Pediatr (2000) 1.91

High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. National Israel Study of Ovarian Cancer. JAMA (1996) 1.90

Mutations of the Gs alpha-subunit gene in Albright hereditary osteodystrophy detected by denaturing gradient gel electrophoresis. Proc Natl Acad Sci U S A (1990) 1.82

The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. Am J Hum Genet (2002) 1.77

What price survival? The future of Blue Cross and Blue Shield. JAMA (1998) 1.75

Genotype-phenotype correlations in Peutz-Jeghers syndrome. J Med Genet (2004) 1.73

A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nat Genet (1997) 1.71

The uninsured. From dilemma to crisis. JAMA (1991) 1.65

Carcinoid tumors frequently display genetic abnormalities involving chromosome 11. J Clin Endocrinol Metab (1996) 1.65

Slicing the pie thinner: hospitals and physicians square off over primary care services. Hospitals (1982) 1.64

The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. Am J Ophthalmol (2000) 1.63

Impaired learning in mice with abnormal short-lived plasticity. Curr Biol (1996) 1.63

Prediction of early course of breast carcinoma by thymidine labeling. Cancer (1983) 1.61

Coping with calamity. How well does health care disaster planning work? JAMA (1994) 1.61

Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int (2010) 1.60

Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol (2002) 1.60

The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. Neurology (2012) 1.56

Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13-21. Circulation (2001) 1.56

New evidence for neurotransmitter influences on brain development. Trends Neurosci (1997) 1.53

Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment. Am J Psychiatry (1992) 1.53

ATM haplotypes and breast cancer risk in Jewish high-risk women. Br J Cancer (2006) 1.47

Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain (1999) 1.45

Mirk protein kinase is a mitogen-activated protein kinase substrate that mediates survival of colon cancer cells. Cancer Res (2000) 1.40

Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science (1992) 1.40

A demanding issue. Healthc Forum J (1996) 1.39

Changing the ranks of medicine. Women MDs. Med World News (1988) 1.39

Chromosomal aberrations and gene expression profiles in non-small cell lung cancer. Lung Cancer (2007) 1.38

Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling. Neuroscience (2005) 1.38

Stimulation of a dopamine D1 receptor enhances inositol phosphates formation in rat brain. J Pharmacol Exp Ther (1990) 1.37

The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim. Hum Mol Genet (1998) 1.37

Induction of SOS functions by alkaline intracellular pH in Escherichia coli. J Bacteriol (1986) 1.36

Digital indocyanine-green angiography in chorioretinal disorders. Ophthalmology (1992) 1.35

Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2004) 1.34

Public hospitals: doing what everyone wants done but few others wish to do. JAMA (1987) 1.34

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer (2012) 1.34

Money isn't everything. Nonfinancial barriers to access. JAMA (1994) 1.34

Squamous cell carcinoma of the transverse duodenum. Gastrointest Endosc (1986) 1.33

Pre-oligodendrocytes from adult human CNS. J Neurosci (1992) 1.29

Evidence for a distinct D1-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain. J Neurochem (1994) 1.28

Disciform degeneration of the macula. II. Pathogenesis. Arch Ophthalmol (1976) 1.26

Hippocampus-dependent learning and memory is impaired in mice lacking the Ras-guanine-nucleotide releasing factor 1 (Ras-GRF1). Neuropharmacology (2001) 1.24

Potent cytodifferentiating agents related to hexamethylenebisacetamide. Proc Natl Acad Sci U S A (1991) 1.23

Limited form of Wegener granulomatosis. Eye involvement as a major sign. JAMA (1975) 1.23

In utero cocaine-induced dysfunction of dopamine D1 receptor signaling and abnormal differentiation of cerebral cortical neurons. J Neurosci (2000) 1.20

Natural history of disciform degeneration of the macula. Am J Ophthalmol (1974) 1.20

Evidence for the coupling of Gq protein to D1-like dopamine sites in rat striatum: possible role in dopamine-mediated inositol phosphate formation. Mol Pharmacol (1995) 1.16

The retinal pigment epithelium. 3. Growth and development. Arch Ophthalmol (1968) 1.14

The retinal pigment epithelium. IV. The damaging effects of radiant energy. Arch Ophthalmol (1968) 1.12

Two different signal transduction pathways can be activated by transforming growth factor beta 1 in epithelial cells. J Biol Chem (1994) 1.12

No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia. Analysis using denaturing gradient gel electrophoresis. JAMA (1994) 1.12

Inhibition of human colonic epithelial cell proliferation in vivo and in vitro by calcium. Cancer Res (1986) 1.11

Prenatal exposure to cocaine selectively reduces D1 dopamine receptor-mediated activation of striatal Gs proteins. J Pharmacol Exp Ther (1995) 1.09

The retinal pigment epithelium. I. Comparative histology. Arch Ophthalmol (1967) 1.09

Acute glomerulonephritis associated with varicella infection. Am J Med (1968) 1.08

Topical diclofenac patch relieves minor sports injury pain: results of a multicenter controlled clinical trial. J Pain Symptom Manage (2000) 1.08

Ibotenate lesions of the hippocampus impair spatial learning but not contextual fear conditioning in mice. Behav Brain Res (1999) 1.08

Naevoid basal cell carcinoma syndrome and Charcot-Marie-Tooth disease: two autosomal dominant disorders segregating in a family. J Med Genet (1978) 1.08

Childhood abuse as a risk for partner abuse among women in methadone maintenance. Am J Drug Alcohol Abuse (1997) 1.07

Family planning services for persons handicapped by mental retardation. Am J Public Health (1976) 1.07

Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer. Hum Mutat (2000) 1.07

Pre-endoscopic medication: parenteral diazepam used adjunctively. Gastrointest Endosc (1970) 1.06

Association of fragile X syndrome with autism. Lancet (1982) 1.06

Allelic loss on chromosome 11 in hereditary and sporadic tumors related to familial multiple endocrine neoplasia type 1. Cancer Res (1991) 1.06

Update of the vascular model of AMD. Br J Ophthalmol (2004) 1.05

Public hospitals often face unmet capital needs, underfunding, uncompensated patient-care costs. JAMA (1987) 1.05

Autism is associated with the fragile-X syndrome. J Autism Dev Disord (1982) 1.05

The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Br J Cancer (2000) 1.05

The sagging safety net. Emergency departments on the brink of crisis. Hospitals (1992) 1.05

Stimulated D(1) dopamine receptors couple to multiple Galpha proteins in different brain regions. J Neurochem (2001) 1.04

Association of the C677T polymorphism in the MTHFR gene with breast and/or ovarian cancer risk in Jewish women. Eur J Cancer (2000) 1.04

The retinal pigment epithelium. II. Histologic changes associated with age. Arch Ophthalmol (1968) 1.03

Long-term prognosis after first Q-wave (transmural) or non-Q-wave (nontransmural) myocardial infarction: analysis of 593 patients. Am J Cardiol (1983) 1.03

Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol Psychiatry (1996) 1.03

Pediatric aerodigestive foreign body injuries are complications related to timeliness of diagnosis. Laryngoscope (1997) 1.02

Metastatic Peptostreptococcus intermedius endophthalmitis after a dental procedure. Am J Ophthalmol (1978) 1.02

The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. Br J Cancer (2001) 1.01

Transforming growth factor beta 1 acts as an autocrine-negative growth regulator in colon enterocytic differentiation but not in goblet cell maturation. Cell Growth Differ (1990) 1.01

Systemic tuberculosis initially seen as an oral ulceration: report of case. J Oral Surg (1978) 1.01

The invasive adenylate cyclase of Bordetella pertussis. Intracellular localization and kinetics of penetration into various cells. Biochem J (1987) 1.01

Maternal Phenylketonuria Collaborative Study (MPKUCS) offspring: facial anomalies, malformations, and early neurological sequelae. Am J Med Genet (1997) 1.00

The invasive adenylate cyclase of Bordetella pertussis. Properties and penetration kinetics. Biochem J (1987) 1.00

12-O-Tetradecanoylphorbol-13-acetate stimulation of DNA synthesis in cultured preneoplastic familial polyposis colonic epithelial cells but not in normal colonic epithelial cells. Cancer Res (1984) 1.00

The restricted nature of HIV-1 tropism for cultured neural cells. Virology (1992) 1.00

Effect of lithium on brain dopamine. Nature (1973) 1.00

The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer (2005) 1.00

beta-Endorphin: effects on respiratory regulation. Life Sci (1978) 1.00

Modulation of lung liquid clearance by isoproterenol in rat lungs. Am J Physiol (1998) 1.00